A Randomized Trial of Tacrolimus versus Tacrolimus and Prednisone for the Maintenance of Disease Remission in Noninfectious Uveitis

Richard W. J. Lee, Rosemary Greenwood, Hazel Taylor, Radgonde Amer, Sabine Biester, Jarka Heissigerova, John V Forrester, Andrew D. Dick

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Purpose
To compare tacrolimus monotherapy with tacrolimus and prednisone therapy for the maintenance of disease remission in subjects with noninfectious posterior segment intraocular inflammation (PSII).

Design
Randomized, controlled, phase 2b, open-label, dual-center noninferiority trial.

Participants
Fifty-eight patients with sight-threatening PSII.

Methods
Patients requiring a second-line systemic immunosuppressive agent to control their PSII were treated with therapeutic doses of oral tacrolimus. Those subjects who subsequently were able to taper their prednisone dose to 10 mg daily without disease reactivation were assigned randomly either to stop prednisone or to continue 7.5 to 10 mg prednisone daily for 9 months.

Main Outcome Measures
Change in logarithm of the minimum angle of resolution (logMAR) visual acuity (VA) and rate of patient withdrawal resulting from treatment inefficacy or intolerance.

Results
Thirty-five patients successfully tapered their prednisone to 10 mg daily. Of these, 16 were allocated randomly to receive tacrolimus monotherapy and 19 to continue taking prednisone and tacrolimus dual therapy. The difference in the mean change in VA for monotherapy compared with the dual therapy group was less than 1 logMAR letter (logMAR, -0.008; 95% confidence interval, -0.108 to 0.092; P = 0.870). The proportion of patients who tolerated treatment and maintained disease remission for 9 months after randomization also was similar in both groups (monotherapy, 62.5%; dual therapy, 68.4%; P = 0.694). All monotherapy treatment failures were the result of disease reactivation, whereas 50% of dual-therapy failures were the result of drug intolerance.

Conclusions
This study provides preliminary evidence that corticosteroids can be withdrawn in tacrolimus-treated patients who are able to achieve control of PSII with 10 mg prednisone daily, and any advantage of dual therapy in the prevention of disease reactivation was offset by its greater treatment intolerance. These findings support the further evaluation of corticosteroid-free treatment in future phase 3 trials (International Standard Randomised Controlled Trial Number Register identification, ISRCTN46576063).

Financial Disclosure(s)
Proprietary or commercial disclosure may be found after the references.
Original languageEnglish
Pages (from-to)1223-1230
Number of pages8
JournalOphthalmology
Volume119
Issue number6
Early online date3 Mar 2012
DOIs
Publication statusPublished - Jun 2012

Fingerprint

Uveitis
Tacrolimus
Prednisone
Maintenance
Inflammation
Therapeutics
Disclosure
Visual Acuity
Adrenal Cortex Hormones
Immunosuppressive Agents
Group Psychotherapy
Random Allocation
Treatment Failure
Randomized Controlled Trials
Confidence Intervals

Cite this

Lee, R. W. J., Greenwood, R., Taylor, H., Amer, R., Biester, S., Heissigerova, J., ... Dick, A. D. (2012). A Randomized Trial of Tacrolimus versus Tacrolimus and Prednisone for the Maintenance of Disease Remission in Noninfectious Uveitis. Ophthalmology, 119(6), 1223-1230. https://doi.org/10.1016/j.ophtha.2011.12.030

A Randomized Trial of Tacrolimus versus Tacrolimus and Prednisone for the Maintenance of Disease Remission in Noninfectious Uveitis. / Lee, Richard W. J.; Greenwood, Rosemary; Taylor, Hazel; Amer, Radgonde; Biester, Sabine; Heissigerova, Jarka; Forrester, John V; Dick, Andrew D.

In: Ophthalmology, Vol. 119, No. 6, 06.2012, p. 1223-1230.

Research output: Contribution to journalArticle

Lee, RWJ, Greenwood, R, Taylor, H, Amer, R, Biester, S, Heissigerova, J, Forrester, JV & Dick, AD 2012, 'A Randomized Trial of Tacrolimus versus Tacrolimus and Prednisone for the Maintenance of Disease Remission in Noninfectious Uveitis' Ophthalmology, vol. 119, no. 6, pp. 1223-1230. https://doi.org/10.1016/j.ophtha.2011.12.030
Lee, Richard W. J. ; Greenwood, Rosemary ; Taylor, Hazel ; Amer, Radgonde ; Biester, Sabine ; Heissigerova, Jarka ; Forrester, John V ; Dick, Andrew D. / A Randomized Trial of Tacrolimus versus Tacrolimus and Prednisone for the Maintenance of Disease Remission in Noninfectious Uveitis. In: Ophthalmology. 2012 ; Vol. 119, No. 6. pp. 1223-1230.
@article{fb67bae1a1934d32a7c90943d2d8661f,
title = "A Randomized Trial of Tacrolimus versus Tacrolimus and Prednisone for the Maintenance of Disease Remission in Noninfectious Uveitis",
abstract = "Purpose To compare tacrolimus monotherapy with tacrolimus and prednisone therapy for the maintenance of disease remission in subjects with noninfectious posterior segment intraocular inflammation (PSII). Design Randomized, controlled, phase 2b, open-label, dual-center noninferiority trial. Participants Fifty-eight patients with sight-threatening PSII. Methods Patients requiring a second-line systemic immunosuppressive agent to control their PSII were treated with therapeutic doses of oral tacrolimus. Those subjects who subsequently were able to taper their prednisone dose to 10 mg daily without disease reactivation were assigned randomly either to stop prednisone or to continue 7.5 to 10 mg prednisone daily for 9 months. Main Outcome Measures Change in logarithm of the minimum angle of resolution (logMAR) visual acuity (VA) and rate of patient withdrawal resulting from treatment inefficacy or intolerance. Results Thirty-five patients successfully tapered their prednisone to 10 mg daily. Of these, 16 were allocated randomly to receive tacrolimus monotherapy and 19 to continue taking prednisone and tacrolimus dual therapy. The difference in the mean change in VA for monotherapy compared with the dual therapy group was less than 1 logMAR letter (logMAR, -0.008; 95{\%} confidence interval, -0.108 to 0.092; P = 0.870). The proportion of patients who tolerated treatment and maintained disease remission for 9 months after randomization also was similar in both groups (monotherapy, 62.5{\%}; dual therapy, 68.4{\%}; P = 0.694). All monotherapy treatment failures were the result of disease reactivation, whereas 50{\%} of dual-therapy failures were the result of drug intolerance. Conclusions This study provides preliminary evidence that corticosteroids can be withdrawn in tacrolimus-treated patients who are able to achieve control of PSII with 10 mg prednisone daily, and any advantage of dual therapy in the prevention of disease reactivation was offset by its greater treatment intolerance. These findings support the further evaluation of corticosteroid-free treatment in future phase 3 trials (International Standard Randomised Controlled Trial Number Register identification, ISRCTN46576063). Financial Disclosure(s) Proprietary or commercial disclosure may be found after the references.",
author = "Lee, {Richard W. J.} and Rosemary Greenwood and Hazel Taylor and Radgonde Amer and Sabine Biester and Jarka Heissigerova and Forrester, {John V} and Dick, {Andrew D.}",
note = "Copyright {\^A}{\circledC} 2012 American Academy of Ophthalmology. Published by Elsevier Inc. All rights reserved.",
year = "2012",
month = "6",
doi = "10.1016/j.ophtha.2011.12.030",
language = "English",
volume = "119",
pages = "1223--1230",
journal = "Ophthalmology",
issn = "0161-6420",
publisher = "Elsevier Inc.",
number = "6",

}

TY - JOUR

T1 - A Randomized Trial of Tacrolimus versus Tacrolimus and Prednisone for the Maintenance of Disease Remission in Noninfectious Uveitis

AU - Lee, Richard W. J.

AU - Greenwood, Rosemary

AU - Taylor, Hazel

AU - Amer, Radgonde

AU - Biester, Sabine

AU - Heissigerova, Jarka

AU - Forrester, John V

AU - Dick, Andrew D.

N1 - Copyright © 2012 American Academy of Ophthalmology. Published by Elsevier Inc. All rights reserved.

PY - 2012/6

Y1 - 2012/6

N2 - Purpose To compare tacrolimus monotherapy with tacrolimus and prednisone therapy for the maintenance of disease remission in subjects with noninfectious posterior segment intraocular inflammation (PSII). Design Randomized, controlled, phase 2b, open-label, dual-center noninferiority trial. Participants Fifty-eight patients with sight-threatening PSII. Methods Patients requiring a second-line systemic immunosuppressive agent to control their PSII were treated with therapeutic doses of oral tacrolimus. Those subjects who subsequently were able to taper their prednisone dose to 10 mg daily without disease reactivation were assigned randomly either to stop prednisone or to continue 7.5 to 10 mg prednisone daily for 9 months. Main Outcome Measures Change in logarithm of the minimum angle of resolution (logMAR) visual acuity (VA) and rate of patient withdrawal resulting from treatment inefficacy or intolerance. Results Thirty-five patients successfully tapered their prednisone to 10 mg daily. Of these, 16 were allocated randomly to receive tacrolimus monotherapy and 19 to continue taking prednisone and tacrolimus dual therapy. The difference in the mean change in VA for monotherapy compared with the dual therapy group was less than 1 logMAR letter (logMAR, -0.008; 95% confidence interval, -0.108 to 0.092; P = 0.870). The proportion of patients who tolerated treatment and maintained disease remission for 9 months after randomization also was similar in both groups (monotherapy, 62.5%; dual therapy, 68.4%; P = 0.694). All monotherapy treatment failures were the result of disease reactivation, whereas 50% of dual-therapy failures were the result of drug intolerance. Conclusions This study provides preliminary evidence that corticosteroids can be withdrawn in tacrolimus-treated patients who are able to achieve control of PSII with 10 mg prednisone daily, and any advantage of dual therapy in the prevention of disease reactivation was offset by its greater treatment intolerance. These findings support the further evaluation of corticosteroid-free treatment in future phase 3 trials (International Standard Randomised Controlled Trial Number Register identification, ISRCTN46576063). Financial Disclosure(s) Proprietary or commercial disclosure may be found after the references.

AB - Purpose To compare tacrolimus monotherapy with tacrolimus and prednisone therapy for the maintenance of disease remission in subjects with noninfectious posterior segment intraocular inflammation (PSII). Design Randomized, controlled, phase 2b, open-label, dual-center noninferiority trial. Participants Fifty-eight patients with sight-threatening PSII. Methods Patients requiring a second-line systemic immunosuppressive agent to control their PSII were treated with therapeutic doses of oral tacrolimus. Those subjects who subsequently were able to taper their prednisone dose to 10 mg daily without disease reactivation were assigned randomly either to stop prednisone or to continue 7.5 to 10 mg prednisone daily for 9 months. Main Outcome Measures Change in logarithm of the minimum angle of resolution (logMAR) visual acuity (VA) and rate of patient withdrawal resulting from treatment inefficacy or intolerance. Results Thirty-five patients successfully tapered their prednisone to 10 mg daily. Of these, 16 were allocated randomly to receive tacrolimus monotherapy and 19 to continue taking prednisone and tacrolimus dual therapy. The difference in the mean change in VA for monotherapy compared with the dual therapy group was less than 1 logMAR letter (logMAR, -0.008; 95% confidence interval, -0.108 to 0.092; P = 0.870). The proportion of patients who tolerated treatment and maintained disease remission for 9 months after randomization also was similar in both groups (monotherapy, 62.5%; dual therapy, 68.4%; P = 0.694). All monotherapy treatment failures were the result of disease reactivation, whereas 50% of dual-therapy failures were the result of drug intolerance. Conclusions This study provides preliminary evidence that corticosteroids can be withdrawn in tacrolimus-treated patients who are able to achieve control of PSII with 10 mg prednisone daily, and any advantage of dual therapy in the prevention of disease reactivation was offset by its greater treatment intolerance. These findings support the further evaluation of corticosteroid-free treatment in future phase 3 trials (International Standard Randomised Controlled Trial Number Register identification, ISRCTN46576063). Financial Disclosure(s) Proprietary or commercial disclosure may be found after the references.

U2 - 10.1016/j.ophtha.2011.12.030

DO - 10.1016/j.ophtha.2011.12.030

M3 - Article

VL - 119

SP - 1223

EP - 1230

JO - Ophthalmology

JF - Ophthalmology

SN - 0161-6420

IS - 6

ER -